Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài:" Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of Gy to a total dose of 29 Gy - Long-term results. | Radiation Oncology BioMed Central Research Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of Gy to a total dose of 29 Gy - Long-term results Matthias Guckenberger 1 Joern Wulf2 Andreas Thalheimer3 Daniel Wehner1 Arnulf Thiede3 Gottfried Muller4 Marco Sailer5 and Michael Flentje1 Address Department of Radiation Oncology University of Wurzburg Wurzburg Germany - Department of Radiooncology Lindenhofspital Bern Switzerland 3Department of Surgery University of Wurzburg Wurzburg Germany 4Department of Surgery Caritas-Krankenhaus Bad Mergentheim Germany and 5Department of Surgery Bethesda - AK Bergedorf Hamburg Germany Email Matthias Guckenberger - Guckenberger_M@ Joern Wulf - wulf@ Andreas Thalheimer - Thalheimer_A@ Daniel Wehner - Arnulf Thiede - Thiede_A@ Gottfried Muller - chirurgie@ Marco Sailer - sailer@ Michael Flentje - Flentje_M@ Corresponding author Open Access Published 21 December 2009 Radiation Oncology 2009 4 67 doi l748-7l 7X-4-67 Received 24 August 2009 Accepted 2l December 2009 This article is available from http content 4 l 67 2009 Guckenberger et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC II. Methods ll8 patients median age 64 years male female ratio l with pathological proven rectal cancer clinical stage II 50 III IV .
